CRISPR Therapeutics, CRSP

Why CRISPR Therapeutics (CRSP) Soared on Friday?
We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other firms that soared on Friday.
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $56.00
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock.
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting principles (GAAP) loss of $37 million ($0.44 per share) against a profit of $98 million in the year-ago quarter.
CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to outperform from in line, citing upcoming catalysts. The investment firm said it was now including the CTX320 and CTX310 in vivo programs in its price target,
CRISPR Therapeutics stock rises following analyst upgrade
CRISPR Therapeutics (NASDAQ: CRSP) stock climbed 7% after receiving an upgrade from Evercore ISI, shifting from an In Line rating to Outperform. The biotechnology company, known for its CRISPR/Cas9 gene-editing platform,
CRISPR system variant shows a novel DNA cleavage mechanism
Researchers have revealed new details about the CRISPR-Cas5-HNH/Cascade complex, a variant of the type I-E CRISPR-Cas system, ...
CRISPR: From Discovery To Clinic—And Charting A Path Forward
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Analysis system enhances rapid pathogen detection with CRISPR technology
A team of researchers from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has developed a ...
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
The Scientist1d
A Gene Drive with a Disappearing Act Can Aid Pest Control
A CRISPR-based system that erases itself from fly populations may offer a safer approach to tackling insecticide resistance ...
Hosted on MSN16h
CRISPR-Cas9 Off-Target Effects: Challenges and Solutions
The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...